Story perspectives

GSK's Bepirovirsen Shows Promise in Hepatitis B Trials

1/7/2026

Summary

Story summary

GlaxoSmithKline (GSK) announced results from phase III trials of bepirovirsen for chronic hepatitis B, which affects over 250 million people worldwide.
The trials showed a significantly higher functional cure rate than placebo and had sustained reductions in hepatitis B surface antigen levels.
GSK plans to file for regulatory approval soon, offering a finite six-month therapy.
Analysts expect peak sales around £2 billion if approved, addressing an unmet hepatitis B need.

1 of 1

Story summary

GlaxoSmithKline (GSK) announced results from phase III trials of bepirovirsen for chronic hepatitis B, which affects over 250 million people worldwide.
The trials showed a significantly higher functional cure rate than placebo and had sustained reductions in hepatitis B surface antigen levels.
GSK plans to file for regulatory approval soon, offering a finite six-month therapy.
Analysts expect peak sales around £2 billion if approved, addressing an unmet hepatitis B need.